Focal therapeutic efficacy of transcatheter arterial infusion of styrene maleic acid neocarzinostatin for hepatocellular carcinoma

Journal of Gastroenterology

Volumn 35, Issue 1, 2000, Pages 28-33

  Abe, Shintaro ^a,b   Okubo, Yoshimitsu ^b   Ejiri, Yutaka ^b   Kume, Keiichiro ^a,b   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b FUKUSHIMA ROSAI HOSPITAL   (Japan)

Author keywords

Epirubicin; Hepatocellular carcinoma; Lipiodol; Styrene maleic acid neocarzinostatin; Transcatheter arterial infusion

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTIC ACID; CHOLINESTERASE; EPIRUBICIN; IODINATED POPPYSEED OIL; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ABDOMINAL PAIN; ADULT; ARTICLE; CATHETER; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; HUMAN; LIVER CELL CARCINOMA; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOM; TUMOR REGRESSION;

EID: 0033958010     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00009972     Document Type: Article

References (24)

1. Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, et al. Effect of arterial administration of high-molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma. A preliminary report. Eur J Cancer Clin Oncol 1983; 19:1053-65.
2. Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M, Miyauchi Y. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumor by arterially administered lipid contrast medium. Cancer 1984;54:2367-74.
3. Nishikawa T, Kumagai K, Kudo A, Kudo A. Cytological study on the effect of neocarzinostatin on Sarcoma 180 in vivo. J Antibiot Tokyo 1965;18:223-7.
4. Meienhofer J, Maeda H, Glaser CB, Czombos J, Kuromizu K. Primary structure of neocarzinostatin, an antitumor protein. Science 1972;178:875-6.
5. Ono Y, Watanabe Y, Ishida N. Mode of action of neocarzinostatin: inhibition of DNA synthesis and degradation of DNA in Sarcina lutea. Biochim Biophys Acta 1966;119:46-58.
6. Konno T. Targeting cancer chemotherapeutic agents by use of Lipiodol contrast medium. Cancer 1990;66:1897-903.
7. Konno T. Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol. Eur J Cancer 1992;28:403-9.
8. Jinno K, Moriwaki S, Tanada M, Wada T, Mandai K, Okada Y, Clinicopathological study on combination therapy consisting of arterial infusion of lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma. Cancer Chemolher Pharmacol 1992;31:7-12.
9. Kato T, Saito Y, Niwa M, Ishiguro J, Ogoshi K. Combination therapy of transcatheter chemoembolization and percutaneous ethanol injection therapy for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 1994;33(Suppl):115-8.
10. Lencioni-R, Paolicchi A, Moretti M, Pinto F, Armillotta N, Di Giulio M, et al. Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and long term survival rate. Eur Radiol 1998;8:439-44.
11. Hirashima N, Sakakibara K, Itazu I, Hirai T, Nemoto A, Matsuura H, et al. Zinostatin stimalamer-transcatheter arterial embolization for hepatocellular carcinoma; a comparison with lipiodol-transcatheter arterial embolization. Semin Oncol 1997; 24(Suppl):91-6.
12. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 1989;19:98-129.
13. Seldinger SI. Catheter replacement of needle in percutanous arteriography: a new technique. Acta Radiol 1953;39:368-76.
14. Maki S, Konno T, Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation for tumor selective drug targeting with oily contrast medium. Cancer 1985;56:751-7.
15. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974;19:331-59.
16. Abrams HL. The response of neoplastic renal vessels to epinephrine in man. Radiology 1964;82:217-24.
17. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219: 983-5.
18. Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on SMANCS. J Protein Chem 1984; 3:181-93.
19. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of protein and antitumor agent SMANCS. Cancer Res 1986;46:6387-92.
20. Peterson HI, Appelgren KL. Experimental studies on the uptake and retention of labeled proteins in a rat tumor. Eur J Cancer 1973;9:543-7.
21. Shibata K, Okubo H, Ishibashi H, Tsuda-Kawamura K, Yanase T. Rat α-1-acid-glycoprotein: uptake by inflammatory and tumor tissue. Br J Exp Pathol 1978;59:601-8.
22. Maeda H, Takeshita J, Kanamaru R. A lipophilic derivative of neocarzinostatin: a polymer conjugation of an anlituinor antibiotic protein. Int J Pept Protein Res 1979;14:81-7.
23. Sakaguchi T, Yoshimatsu S, Sagara K, Yamashita Y, Takahashi M. Intra-arterial infusion of SMANCS for treatment of patients with hepatocellular carcinoma-adverse reactions and complications (in Japanese). Gan-To-Kagaku-Ryoho (Jpn J Cancer Chemother) 1998;25(Suppl 1):64-9.
24. Okusaka T, Okada S, Ishii H, Ikeda M, Nakasuka H, Nagahama H, et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology 1998;55:276-83.